Soleno Therapeutics, Inc.
Price Action
Technical Summary
CONSOLIDATINGSoleno Therapeutics, Inc. is in a consolidation phase, trading with mixed signals as moving averages converge. Relative strength is leading (RS Rating: 85), indicating clear outperformance against the broad market. Earnings growth of 162% provides fundamental context to the price action. However, with RSI at 78, the stock is extended and may be prone to a short-term pullback.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $52.87 | +0.26% | ABOVE |
| 50 SMA | $45.79 | +15.77% | ABOVE |
| 100 SMA | $43.89 | +20.77% | ABOVE |
| 150 SMA | $47.49 | +11.63% | ABOVE |
| 200 SMA | $52.40 | +1.17% | ABOVE |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is SLNO in an uptrend right now?
SLNO has a trend score of 2/4 based on Minervini's Stage Analysis. Currently showing partial alignment - 2 of 4 trend criteria are met.
Is SLNO overbought or oversold?
SLNO's RSI (14) is 78. The stock is in overbought territory (RSI > 70), which may signal a pullback.
Is SLNO outperforming the market?
SLNO has a Relative Strength (RS) Rating of 85 out of 99. Yes, SLNO is a market leader, outperforming 85% of all stocks over the past 12 months.
Where is SLNO in its 52-week range?
SLNO is trading at $53.01, which is 59% of its 52-week high ($90.32) and 39% above its 52-week low ($29.47).
How volatile is SLNO?
SLNO has a Beta of 1.00 and 52-week volatility of 72%. It's less volatile than the S&P 500 - generally more stable.